IFNA1 and cystic fibrosis: The antiviral effects of azithromycin shown in previous studies in healthy BECs and cystic fibrosis (CF) BECs were both modest and variable, producing up to 200%–500% augmentation of type I and type III IFN induction following RV infection, but with limited potency in vitro.28,29 We therefore embarked on a screen of 225 novel macrolides in an attempt to identify compounds with stronger effects on innate host responses to RV in terms of both efficacy and potency.